论文部分内容阅读
近几年来干扰素抗癌能力已引起极大的注意。早在1957年它是作为干扰病毒感染的一种蛋白质而被发现。干扰素已成为临床上和实验室中新研究的焦点。由于用作研究的天然产生的干扰素量少,早期的研究受到限制。但是,现代分子生物学的尖端技术已被用于为临床试验产生足量干扰素的问题。关于人体干扰素的编码基因已克隆化并且与细菌质重新组合。这样的质粒已用来侵染细菌,然后这种被侵染的细菌在培养基中生长,以获得高度纯化的干扰素。现在已有两家药厂正在生产大量的“重组”干扰素。
In recent years, the ability of interferon to fight cancer has attracted great attention. As early as 1957 it was discovered as a protein that interferes with viral infection. Interferons have become the focus of new research in the clinical and laboratory. Due to the small amount of naturally occurring interferon used as a research, early studies were limited. However, cutting-edge technologies in modern molecular biology have been used to generate enough interferon for clinical trials. The coding gene for human interferon has been cloned and recombined with the bacterial mass. Such plasmids have been used to infect bacteria, and the infested bacteria are then grown in culture to obtain highly purified interferons. Two pharmaceutical companies are now producing large quantities of “recombinant” interferons.